JNJ
Pharma

J&J's Caplyta scores 2nd ph. 3 win in bipolar mania

Touting “consistent evidence” from two phase 3 studies, J&J said the Caplyta data will support its planned submission for an FDA approval.
Angus Liu Nov 10, 2026 10:01am
Asking More of Science How Daiichi Sankyo Is Challenging Assumptions About the Future of Cancer Care

Asking More of Science: How Daiichi Sankyo Is Challenging Assumptions About the Future of Cancer Care

Brought to you by Daiichi Sankyo, Inc.
Business person contemplating how to navigate a maze made of money
Favicon Fierce Biotech

Why experts fear fallout from Treasury’s China biotech crackdown

Nov 10, 2026 9:30am
WuXi

WuXi AppTec removed from US list of Chinese military companies

Nov 10, 2026 8:51am
law and order concept

FDA orders GLP-1s add eye risk to labels

Nov 10, 2026 8:31am
Insulet Gluconaut Marvel comic

Insulet’s Marvel collab returns with new diabetes superhero

Nov 10, 2026 7:00am
More News

Vertex layoffs hit 78 Crinetics employees following $10B deal

Nov 10, 2026 3:00am

Bayer nabs 1st-in-class FDA nod for stroke med asundexian

Nov 9, 2026 9:10pm

Veradermics’ oral hair loss drug passes 1-year ph. 3 test

Nov 9, 2026 2:52pm

FDA probes Novartis’ Zolgensma gene therapy over cancer risks

Nov 9, 2026 11:14am